View Older Stories View More Recent Stories
-
Vertex (VRTX) PT Lowered to $445 at Stifel
-
Cantor Fitzgerald Reiterates Overweight Rating on Vertex (VRTX)
-
Vertex (VRTX) PT Lowered at BMO Capital Amid 'Greater Near-Term Complexity'
-
Vertex (VRTX) PT Lowered to $466 at Bernstein SocGen Group
-
Vertex Pharma (VRTX) Tops Q3 EPS by 23c, provides guidance
-
Vertex Pharma (VRTX) call put ratio 15 call to 1 put into quarter results
-
Vertex Pharma (VRTX) call put ratio 1 call to 1.9 puts into quarter results
-
Bernstein's US Biotech 3Q25 Preview: 'Expect Beats from ALNY and REGN'
-
VERTEX presents data on cystic fibrosis drugs at conference
-
Citizens Reiterates Vertex (VRTX) at Market Outperform Rating; Management Sees Revenue Above Consensus
-
Vertex receives FDA rolling review for kidney disease drug povetacicept
-
Biotech stocks: Q3 earnings preview
-
Cantor Fitzgerald Reiterates Overweight Rating on Vertex (VRTX)
-
Vertex (VRTX) PT Raised to $423 at RBC Capital
-
Canaccord #1 Key Risk to AxoGen, Inc. (AXGN): 'the FDA running out of carryover funding and needing to halt work'
-
FDA on Operations During Shutdown: 'FDA will not be able to accept any regulatory submissions for FY 2026 that require a fee payment'
-
Vertex receives FDA breakthrough therapy designation for kidney drug
-
Leerink Partners Upgrades Vertex (VRTX) to Outperform
-
Vertex secures Italian reimbursement deal for gene therapy CASGEVY
-
Goldman Sachs Reiterates Buy Rating on Vertex (VRTX)
-
Vertex (VRTX) PT Lowered to $34 at BofA Securities
-
Vertex (VRTX) PT Lowered to $411 at Canaccord Genuity
-
Vertex (VRTX) PT Lowered to $405 at RBC Capital Amid Setbacks
-
Vertex (VRTX) PT Lowered to $530 at BMO Capital
-
Vertex (VRTX) PT Lowered to $455 at Stifel
-
Vertex (VRTX) PT Raised to $471 at Bernstein SocGen Group
-
Vertex (VRTX) PT Lowered to $485 at Cantor Fitzgerald
-
Vertex (VRTX) PT Lowered to $490 at Truist Securities
-
Vertex (VRTX) PT Lowered to $478 at H.C. Wainwright
-
Vertex (VRTX) PT Lowered to $458 at Leerink Partners
-
Vertex (VRTX) PT Lowered to $553 at UBS
-
After-hours movers: Palantir, Hims & Hers, Vertex Pharma and more
-
Vertex Pharma (VRTX) Tops Q2 EPS by 25c, Beats on Revenue; Offers FY25 Revenue Guidance
-
Vertex Pharma (VRTX) call put ratio 1.4 calls to 1 put into quarter results
-
Vertex Pharma (VRTX) call put ratio 1 call to 1.3 puts into quarter results
-
Vertex (VRTX) PT Lowered to $38 at BMO Capital
-
Vertex Pharma (VRTX) receives marketing authorization in Canada for Alyftrek
-
U.S. large biotech stocks Q2 earnings preview
-
Vertex Pharma (VRTX) Announces European Commission Approval of ALYFTREK
-
William Blair Reiterates Outperform Rating on Vertex (VRTX)
-
H.C. Wainwright Reiterates Buy Rating on Vertex (VRTX)
-
Vertex (VRTX) PT Lowered to $420 at RBC Capital
-
Vertex Pharma (VRTX) reveals new data on ALYFTREK
-
RBC Capital weighs in on Vertex (VRTX) following IgAN competitor data
-
FDA Cell and Gene Therapy Roundtable 'bullish for the space' - Stifel
-
Stifel on Sionna Therapeutics (SION): 'both compounds are able to attain exposures well above the modeled PK threshold'
-
BofA Securities Reiterates Buy Rating on Vertex (VRTX)
-
BMO Capital Reiterates Outperform Rating on Vertex (VRTX)
-
UBS Reiterates Buy Rating on Vertex (VRTX) after positive doc call on Journavx uptake
-
Erste Group Downgrades Vertex (VRTX) to Hold, 'The ratio of receivables to sales is also at a very high level'
